New Triple-Drug hair loss treatment enters final testing phase

NCT ID NCT07435012

Recruiting now Disease control Sponsor: Triple Hair Inc Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests a new topical solution called TH07 for male pattern baldness. It combines three active ingredients (minoxidil, finasteride, and latanoprost) to see if it grows more hair than standard minoxidil or a placebo. 420 men aged 18-49 with moderate hair loss will apply the treatment daily for 24 weeks, and hair growth will be measured using special photography.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TH07 (a combination of minoxidil, finasteride, and latanoprost)
What this could lead to: If successful, TH07 could offer a more effective topical treatment for male pattern baldness, potentially increasing hair count and thickness better than current options.
What could go wrong: This is a Phase 3 trial, but results may not show a significant advantage over existing treatments. Side effects from the drug combination are possible, and individual results vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANDROGENIC ALOPECIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alopecia androgenetic alopecia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANDROGENIC ALOPECIA

Contacts and locations

Locations

YVR Aesthetic Training and Study Centre.
RECRUITING

Vancouver, British Columbia, V5Z1H2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.